Keyphrases
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
100%
Lung Adenocarcinoma
100%
Oligoprogression
100%
Tumor
50%
Targeted Therapy
25%
Disease Control
25%
Positive Impact
25%
Primary Tumor
25%
Overall Survival
25%
Lung Cancer Patients
25%
Lung Cancer
25%
Biological Potential
25%
Local Treatment
25%
Complete Response
25%
Initial Diagnosis
25%
Biological Objects
25%
Third Generation
25%
Osimertinib
25%
Disease Control Rate
25%
Ablative
25%
Multidisciplinary Tumor Board
25%
Primary Tumor Resection
25%
Primary Resection
25%
Medicine and Dentistry
Diseases
100%
Epidermal Growth Factor Receptor
100%
Lung Adenocarcinoma
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Primary Tumor
75%
Neoplasm
50%
Lung Cancer
50%
Overall Survival
25%
Local Therapy
25%
Cancer Surgery
25%
Osimertinib
25%
Targeted Therapy
25%
Surgery
25%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Epidermal Growth Factor Receptor
100%
Lung Adenocarcinoma
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Primary Tumor
75%
Neoplasm
50%
Lung Cancer
50%
Overall Survival
25%
Osimertinib
25%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Receptor Tyrosine Kinase Inhibitors
50%
Overall Survival
12%